PITTSBURGH - Predictive Oncology Inc. (NASDAQ: NASDAQ:POAI), a company specializing in AI-driven drug discovery, has announced the results of a study confirming the long-term stability of its biobank's cryopreserved patient tumor samples. The study showcases the reproducibility of drug response data from samples stored for up to 16 years, which is vital for predicting patient outcomes and personalizing therapies.
The company's biobank contains over 150,000 tumor specimens and 200,000 pathology slides, along with two decades of drug and tumor response data. This extensive collection of samples and data is instrumental in aiding drug developers to better understand patient heterogeneity and to validate targets and biomarkers well ahead of human clinical trials.
Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery (NASDAQ:WBD) at Predictive Oncology, expressed satisfaction with the study's outcome, which demonstrated a 100% concordance rate between the original fresh patient sample testing and the cryogenically stored material. This result underlines the reliability of the data collected over many years and the utility of the biobank.
Raymond Vennare, CEO of Predictive Oncology, highlighted the company's unique position in building models that can accurately predict patient outcomes. He emphasized the value of the biobank not only to the company but also to its partners in drug development.
The global biospecimen market, valued at $4.4 billion in 2023, is expected to see significant growth, with projections reaching $11.7 billion by 2031. Predictive Oncology's recent study and its AI/ML platform, which boasts a 92% accuracy rate in predicting tumor sample responses to drug compounds, positions the company to capitalize on this expanding market.
Alongside the study results, Predictive Oncology has released a white paper detailing the importance of tumor sample viability. This document serves as an additional resource for those interested in the technical aspects of the study.
The company, with its headquarters in Pittsburgh, PA, continues to advance in the field of biomarker and drug discovery, leveraging its proprietary technology and extensive biobank to support the development of cancer treatments.
This article is based on a press release statement from Predictive Oncology Inc.
In other recent news, Predictive Oncology has reported its Q2 2024 financial results, revealing a decrease in revenue to $279,000 from $490,000 in the same quarter of the previous year. However, the company's net loss per share has been reduced to $0.68 from $0.98. The firm has completed a significant ovarian cancer study with UPMC Magee-Womens Hospital and launched a 3D cell culture technology.
Predictive Oncology has underscored its commitment to advancing biomarker discovery and developing next-generation therapies in oncology. The company's recent initiatives include the expansion of artificial intelligence and machine learning capabilities for biomarker discovery, as well as cost reduction measures such as consolidating operations in Pittsburgh.
Despite a decline in revenue, the company has successfully raised $5 million in capital and has managed to decrease its net cash usage to $6.6 million for the six months ended June 30, 2024. While the company continues to operate at a loss, with an accumulated deficit of $175 million, the reduction in net loss per share indicates improved financial performance.
InvestingPro Insights
As Predictive Oncology Inc. (NASDAQ: POAI) solidifies its standing in the biobanking and drug discovery industry with its recent study, financial metrics from InvestingPro offer a snapshot of the company's market position. With a market capitalization of $6 million, the company is navigating the competitive landscape of the biospecimen market. Despite the potential for growth in the sector, analysts anticipate a sales decline for the current year, which could be a factor for potential investors to consider.
InvestingPro data reveals that Predictive Oncology holds a Price to Book ratio of 1.47 as of the last twelve months ending Q2 2024, which can offer insights into the company's valuation relative to its net asset value. Moreover, the company's revenue growth has seen a notable increase of 12.85% during the same period, highlighting its ability to generate income amidst challenging market conditions. However, it's important to note that the company's Operating Income Margin stands at -805.63%, reflecting the expenses outweighing the operating income.
Among the InvestingPro Tips, two notable points stand out for Predictive Oncology. Firstly, the company holds more cash than debt on its balance sheet, which is a positive sign of financial health and could provide some stability in its operational endeavors. Secondly, and contrasting this positive aspect, the company is quickly burning through cash, which raises questions about its long-term financial sustainability and could be a concern for investors.
For those interested in a deeper analysis, InvestingPro offers additional tips on Predictive Oncology, including insights on valuation, stock performance, and profitability. There are 12 more InvestingPro Tips available, which can be accessed at the dedicated InvestingPro page for Predictive Oncology (https://www.investing.com/pro/POAI).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.